Increased small intestinal permeability in ulcerative colitis: Rather genetic than environmental and a risk factor for extensive disease?

Inflammatory Bowel Diseases

Volumn 18, Issue 10, 2012, Pages 1932-1939

  Büning, Carsten ^a   Geissler, Nora ^a   Prager, Matthias ^a   Sturm, Andreas ^a   Baumgart, Daniel C ^a   Büttner, Janine ^a   Bühner, Sabine ^b   Haas, Verena ^c   Lochs, Herbert ^d  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c FRANZ VOLHARD CLINIC   (Germany)

^d INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

colonic permeability; fecal calprotectin; healthy relatives; small intestinal permeability; spouses; ulcerative colitis

Indexed keywords

ACETYLSALICYLIC ACID; AZATHIOPRINE; BUDESONIDE; CALGRANULIN; LACTULOSE; MANNITOL; MERCAPTOPURINE; PREDNISOLONE; SUCRALOSE; SUCROSE;

ADULT; ARTICLE; CONTROLLED STUDY; CORTICOSTEROID THERAPY; ENVIRONMENTAL FACTOR; FAMILY STUDY; FEMALE; GENETIC RISK; HISTOPATHOLOGY; HOUSEHOLD; HUMAN; IN VIVO STUDY; INTESTINE MUCOSA PERMEABILITY; MAJOR CLINICAL STUDY; MALE; PANCOLITIS; PRIORITY JOURNAL; PROCTITIS; REMISSION; ULCERATIVE COLITIS;

6-MERCAPTOPURINE; ADULT; AZATHIOPRINE; CASE-CONTROL STUDIES; COLITIS, ULCERATIVE; COLON; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTESTINAL ABSORPTION; INTESTINE, SMALL; MALE; PERMEABILITY; PROCTITIS; REMISSION INDUCTION; RISK FACTORS; SPOUSES; SUCROSE; TISSUE DISTRIBUTION;

EID: 84866424847     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.22909     Document Type: Article

References (51)

1. Teahon K, Smethurst P, Levi AJ, et al. Intestinal permeability in patients with Crohn's disease and their first degree relatives. Gut. 1992; 33: 320-323.
2. Söderholm JD, Olaison G, Lindberg E, et al. Different intestinal permeability patterns in relatives and spouses of patients with Crohn's disease: an inherited defect in mucosal defence? Gut. 1999; 44: 96-100. (Pubitemid 29143287)
3. Peeters M, Geypens B, Claus D, et al. Clustering of increased small intestinal permeability in families with Crohn's disease. Gastroenterology. 1997; 113: 802-807. (Pubitemid 27381139)
4. D'Incà R, Annese V, di Leo V, et al. Increased intestinal permeability and NOD2 variants in familial and sporadic Crohn's disease. Aliment Pharmacol Ther. 2006; 23: 1455-1461.
5. Fries W, Renda MC, Lo Presti MA, et al. Intestinal permeability and genetic determinants in patients, first-degree relatives, and controls in a high-incidence area of Crohn's disease in southern Italy. Am J Gastroenterol. 2005; 100: 2730-2736.
6. Irvine EJ, Marshall JK,. Increased intestinal permeability precedes the onset of Crohn's disease in a subject with familial risk. Gastroenterology. 2000; 119: 1740-1744. (Pubitemid 32198699)
7. Wyatt J, Vogelsang H, Hübl W, et al. Intestinal permeability and the prediction of relapse in Crohn's disease. Lancet. 1993; 341: 1437-1439. (Pubitemid 23161445)
8. Buhner S, Buning C, Genschel J, et al. Genetic basis for increased intestinal permeability in families with Crohn's disease: role of CARD15 3020insC mutation? Gut. 2006; 55: 342-347. (Pubitemid 43268271)
9. Stange EF, Travis S, Vermeire S,. European evidence-based Consensus on the diagnosis and management of ulcerative colitis: definitions and diagnosis. J Crohns Colitis. 2008; 2: 1-23. (Pubitemid 351179487)
10. Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol. 2005; 19 (Suppl A): 5-36.
11. Haas V, Büning C, Buhner S, et al. Clinical relevance of measuring colonic permeability. Eur J Clin Invest. 2009; 39: 139-144.
12. Arslan G, Atasever T, Cindoruk M, et al. (51)CrEDTA colonic permeability and therapy response in patients with ulcerative colitis. Nucl Med Commun. 2001; 22: 997-1001. (Pubitemid 32783451)
13. Casellas F, Aguadé S, Soriano B, et al. Intestinal permeability to 99mTc-diethylenetriaminopentaacetic acid in inflammatory bowel disease. Am J Gastroenterol. 1986; 81: 767-770. (Pubitemid 16024857)
14. Issenman RM, Jenkins RT, Radoja C,. Intestinal permeability compared in pediatric and adult patients with inflammatory bowel disease. Clin Invest Med. 1993; 16: 187-196. (Pubitemid 23252678)
15. Jenkins RT, Jones DB, Goodacre RL, et al. Reversibility of increased intestinal permeability to 51Cr-EDTA in patients with gastrointestinal inflammatory diseases. Am J Gastroenterol. 1987; 82: 1159-1164 (Pubitemid 18013111)
16. Jenkins AP, Nukajam WS, Menzies IS, et al. Simultaneous administration of lactulose and 51Cr-ethylenediaminetetraacetic acid. A test to distinguish colonic from small-intestinal permeability change. Scand J Gastroenterol. 1992; 27: 769-773.
17. Miki K, Moore D, Butler R, et al. The sugar permeability test reflects disease activity in children and adolescents with inflammatory bowel disease. J Pediatr. 1998; 133: 750-754. (Pubitemid 28563943)
18. Resnick RH, Royal H, Marshall W, et al. Intestinal permeability in gastrointestinal disorders. Use of oral [99mTc]DTPA. Dig Dis Sci. 1990; 35: 205-211. (Pubitemid 20072194)
19. Teahon K, Somasundaram S, Smith T, et al. Assessing the site of increased intestinal permeability in coeliac and inflammatory bowel disease. Gut. 1996; 38: 864-869. (Pubitemid 26231771)
20. Welcker K, Martin A, Kölle P, et al. Increased intestinal permeability in patients with inflammatory bowel disease. Eur J Med Res. 2004; 9: 456-460.
21. Jenkins R, Goodacre R, Rooney P, et al. Studies of intestinal diseases using permeability in inflammatory bowel diseases using polyethylene glycol 400. Clin Biochem. 1986; 19: 298-302. (Pubitemid 16006517)
22. Lobley RW, Burrows PC, Warwick R, et al. Simultaneous assessment of intestinal permeability and lactose tolerance with orally administered raffinose, lactose and L-arabinose. Clin Sci (Lond). 1990; 79: 175-183. (Pubitemid 20218958)
23. Munkholm, P, Langholz E, Hollander D, et al. Intestinal permeability in patients with Crohn's disease and ulcerative colitis and their first degree relatives. Gut. 1994; 35: 68-72. (Pubitemid 24059475)
24. Peled Y, Watz C, Gilat T,. Measurement of intestinal permeability using 51Cr-EDTA. Am J Gastroenterol. 1985; 80: 770-773. (Pubitemid 16232291)
25. Gursoy S, Guven K, Kula M, et al. Subclinical alveolar involvement in ulcerative colitis. Inflamm Bowel Dis. 2005; 11: 372-375. (Pubitemid 40542269)
26. Miele E, Pascarella F, Quaglietta L, et al. Altered intestinal permeability is predictive of early relapse in children with steroid-responsive ulcerative colitis. Aliment Pharmacol Ther. 2001; 25: 933-939.
27. Røseth AG, Aadland E, Jahnsen J, et al. Assessment of disease activity in ulcerative colitis by faecal calprotectin, a novel granulocyte marker protein. Digestion. 1997; 58: 176-180. (Pubitemid 27163169)
28. Silberer H, Küppers B, Mickisch O, et al. Fecal leukocyte proteins in inflammatory bowel disease and irritable bowel syndrome. Clin Lab. 2005; 51: 117-126. (Pubitemid 40520584)
29. Langhorst J, Elsenbruch S, Kolezer J, et al. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: pPerformance of fecal lactoferrin, calprotectin, and PMN-Elastase, CRP, and clinical indices. Am J Gastroenterol. 2008; 103: 162-169.
30. Schoepfer A, Beglinger C, Straumann A, et al. Fecal calprotectin correlates more closely with the simple endoscopic score for Crohn's disease (SES-CD) than CRP, blood leukocytes, and the CDAI. Am J Gastroenterol. 2010; 105: 162-169.
31. Walkiewicz D, Werlin SL, Fish D, et al. Fecal calprotectin is useful in predicting disease relapse in pediatric inflammatory bowel disease. Inflamm Bowel Dis. 2008; 14: 669-673. (Pubitemid 351742984)
32. D'Incà R, Dal Pont E, Di Leo V, et al. Can calprotectin predict relapse risk in inflammatory bowel disease? Am J Gastroenterol. 2008; 103: 2007-2014.
33. Etchevers M, Aceituno M, Garcia-Bosch O, et al. Risk factors and characteristics of extent progression in ulcerative colitis. Inflamm Bowel Dis. 2009; 15: 1320-1325.
34. Pierik M, Joossens S, Vermiere S, et al. Toll-like receptor-1, -2 and -6 polymorphisms influence disease extension in inflammatory bowel diseases. Inflamm Bowel Dis. 2006; 12: 1-8. (Pubitemid 43032444)
35. Arrieta MC, Madsen K, Doyle J, et al. Reducing small intestinal permeability attenuates colitis in the IL10 gene-deficient mouse. Gut. 2009; 58: 41-48.
36. Mazzon E, Cuzzocrea S,. Thalidomide treatment reduces the alteration of paracellular barrier function in mice ileum during experimental colitis. Shock. 2006; 25: 515-521.
37. Mazzon E, Cuzzocrea S,. Absence of functional peroxisome proliferator-activated receptor-alpha enhanced ileum permeability during experimental colitis. Shock. 2007; 28: 192-201. (Pubitemid 47220831)
38. Suenaert P, Bulteel V, Lemmens L, et al. Anti-tumor necrosis factor treatment restores the gut barrier in Crohn's Disease. Am J Gastroenterol. 2002; 97: 2000-2004.
39. Teahon K, Smethurst P, Levi AJ, et al. The effect of elemental diet on intestinal permeability and inflammation in Crohn's disease. Gastroenterology. 1991; 101: 84-89.
40. Lennard L,. The clinical pharmacology of 6-mercaptopurine. Eur J Clin Pharmacol. 1992; 43: 329-339.
41. Ben-Horin S, Goldstein I, Fudim E, et al. Early preservation of effector functions followed by eventual T cell memory depletion: a model for the delayed onset of the effect of thiopurines. Gut. 2009; 58: 398-403.
42. Swidsinski A, Loening-Baucke V, Bengmrak S, et al. Azathioprine and mesalazine-induced effects on the mucosal flora in patients with IBD colitis. Inflamm Bowel Dis. 2007; 13: 51-56. (Pubitemid 46080009)
43. Jenkins RT, Ramage JK, Jones DB, et al. Small bowel and colonic permeability to 51Cr-EDTA in patients with active inflammatory bowel disease. Clin Invest Med. 1988; 11: 151-155.
44. Schulzke J, Ploeger S, Amasheh M, et al. Epithelial tight junctions in intestinal inflammation. Ann N Y Acad Sci. 2009; 1165: 294-300.
45. Schurmann G, Bruwer M, Klotz A, et al. Transepithelial transport processes at the intestinal mucosa in inflammatory bowel disease. Int J Colorectal Dis. 1999; 14: 41-46. (Pubitemid 29295302)
46. Nejdfors P, Wang Q, Ekelund M, et al. Increased colonic permeability in patients with ulcerative colitis: an in vitro study. Scand J Gastroenterol. 1998; 33: 749-753. (Pubitemid 28358060)
47. Wallon C, Persborn M, Jönsson M, et al. Eosinophils express muscarinic receptors and corticotropin-releasing factor to disrupt the mucosal barrier in ulcerative colitis. Gastroenterology. 2011; 140: 1597-1607.
48. Fisher S, Tremelling M, Anderson C, et al. Genetic determinants of ulcerative colitis include the ECM1 locus and five loci implicated in Crohn's disease. Nat Genet. 2008; 40: 710-712. (Pubitemid 351748865)
49. The UK IBD Genetics Consortium & the Wellcome Trust Case Control Consortium. Genome-wide association study of ulcerative colitis identifies three new susceptibility loci, including the HNF4A region. Nat Genet. 2009; 41: 1330-1336.
50. Wapenaar MC, Monsuur AJ, van Bodegraven AA, et al. Associations with tight junction genes PARD3 and MAGI2 in Dutch patients point to a common barrier defect for coeliac disease and ulcerative colitis. Gut. 2008; 57: 463-467. (Pubitemid 351442527)
51. McGovern D, Taylor K, Landers C, et al. MAGI2 genetic variation and inflammatory bowel disease. Inflamm Bowel Dis. 2009; 15: 75-83.